News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
|Articles|October 1, 2018

Targeting the Affluent Fig1

Author(s)Pieter De Richter
Advertisement
External Link - IpsosChinaFig1.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
President Donald J. Trump

President Trump Planning to Fire FDA Commissioner Marty Makary: Report

ByNicholas Jacobus
May 8th 2026
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA

ByNicholas Jacobus
May 8th 2026
Stock.adobe.com FDA HQ

FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection

ByNicholas Jacobus
May 8th 2026
Akila and Patil

GLP-1 Patent Expiry & the Rise of Generics: Transforming the Drug Delivery Device Landscape & Procurement Strategy

ByS. Akila
May 8th 2026
Hogenboom and Zobel

Factors Contributing to the Growth of Radiopharmaceuticals: Q&A with Andrea Zobel and Marco Hogenboom

ByMike Hollan,Andrea Zobel,Marco Hogenboom
May 8th 2026
Advertisement
Advertisement

Trending on PharmExec

1

President Trump Planning to Fire FDA Commissioner Marty Makary: Report

2

GLP-1 Patent Expiry & the Rise of Generics: Transforming the Drug Delivery Device Landscape & Procurement Strategy

3

Factors Contributing to the Growth of Radiopharmaceuticals: Q&A with Andrea Zobel and Marco Hogenboom

4

FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection

5

Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us